Reata Pharmaceuticals (NASDAQ:RETA) Lowered to Market Perform at SVB Securities

Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report) was downgraded by equities research analysts at SVB Securities from an “outperform” rating to a “market perform” rating in a research report issued on Friday, FlyOnTheWall reports. Several other analysts have also commented on the stock. Stifel Nicolaus lowered shares of Reata Pharmaceuticals from a “buy” rating to […]

Related Keywords

China ,Andrea Loewen ,Michaeld Wortley ,Stifel Nicolaus ,Barclays ,Reata Pharmaceuticals ,News Ratings For Reata Pharmaceuticals Daily ,International Assets Investment Management ,Reata Pharmaceuticals Company Profile ,Belpointe Asset Management ,Reata Pharmaceuticals Trading ,Reata Pharmaceuticals Inc ,Nisa Investment Advisors ,Analyst Recommendations For Reata Pharmaceuticals ,China Universal Asset Management Co ,Tower Research Capital ,Nasdaq ,Hedge Funds Weigh In On Reata Pharmaceuticals ,Get Free Report ,Asset Management ,Assets Investment Management ,Universal Asset Management ,Investment Advisors ,Research Capital ,Reata Pharmaceuticals Daily ,